Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Efficient inhibition of growth of metastatic cancer cells after resection of primary colorectal cancer by soluble Flt-1

  • Research Article
  • Published:
Tumor Biology

This article was retracted on 20 April 2017

Abstract

Removal of primary tumors often leads to increases in growth of metastatic tumor cells. Thus, development of an efficient treatment to inhibit the growth of metastatic tumor cells after resection of primary tumors appears to be critical for cancer therapy. Here, we reported that administration of a Chinese medicine Shiquandabutao (SQDBT) after removal of the primary cancer significantly inhibited the growth of metastatic cancer cells in mouse liver. Further analyses showed that the effect of SQDBT resulted from one of its main component, Siwutang (SWT), rather than from another main component, Sijunzitang (SJZT). Moreover, we found that the soluble Flt-1 from SWT neutralized the increased placental growth factor (PLGF) secreted by the metastatic cancer cells after primary cancer resection and subsequently inhibited the cancer neovascularization to suppress the metastatic cancer growth. Thus, our study reveals an essential role of SQDBT in inhibiting the growth of metastatic cancer after removal of primary cancer and further highlights PLGF as a potential target for metastatic cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008;19:1821–8.

    Article  CAS  PubMed  Google Scholar 

  2. Aliperti LA, Predina JD, Vachani A, Singhal S. Local and systemic recurrence is the achilles heel of cancer surgery. Ann Surg Oncol. 2011;18:603–7.

    Article  PubMed  Google Scholar 

  3. Curcio LD, Chu DZ, Ahn C, Williams Jr WL, Paz IB, Riihimaki D, et al. Local recurrence in breast cancer: implications for systemic disease. Ann Surg Oncol. 1997;4:24–7.

    Article  CAS  PubMed  Google Scholar 

  4. Kosari K, Gomes M, Hunter D, Hess DJ, Greeno E, Sielaff TD. Local, intrahepatic, and systemic recurrence patterns after radiofrequency ablation of hepatic malignancies. J Gastrointest Surg. 2002;6:255–63.

    Article  PubMed  Google Scholar 

  5. Scott AD, Crane P, Staunton MD. Chondrosarcoma—local recurrence and systemic embolization. J R Soc Med. 1990;83:48–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789–91.

    Article  CAS  PubMed  Google Scholar 

  7. Eichmann A, Simons M. Vegf signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol. 2012;24:188–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, Zhou D, et al. Placenta growth factor-1 antagonizes vegf-induced angiogenesis and tumor growth by the formation of functionally inactive plgf-1/vegf heterodimers. Cancer Cell. 2002;1:99–108.

    Article  CAS  PubMed  Google Scholar 

  9. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-plgf inhibits growth of vegf(r)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131:463–75.

    Article  CAS  PubMed  Google Scholar 

  10. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al. Role of plgf in the intra- and intermolecular cross talk between the vegf receptors flt1 and flk1. Nat Med. 2003;9:936–43.

    Article  CAS  PubMed  Google Scholar 

  11. Xiao X, Prasadan K, Guo P, El-Gohary Y, Fischbach S, Wiersch J, et al. Pancreatic duct cells as a source of vegf in mice. Diabetologia. 2014;57:991–1000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, et al. Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem. 2013;288:8636–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth. Cancer Res. 2000;60:2190–6.

    CAS  PubMed  Google Scholar 

  14. Indraccolo S, Minuzzo S, Gola E, Habeler W, Carrozzino F, Noonan D, et al. Generation of expression plasmids for angiostatin, endostatin and timp-2 for cancer gene therapy. Int J Biol Markers. 1999;14:251–6.

    CAS  PubMed  Google Scholar 

  15. Harris AL. Are angiostatin and endostatin cures for cancer? Lancet. 1998;351:1598–9.

    Article  CAS  PubMed  Google Scholar 

  16. Huang SM, Chien LY, Tai CJ, Chiou JF, Chen CS, Tai CJ. Effectiveness of 3-week intervention of shi quan da bu tang for alleviating hematotoxicity among patients with breast carcinoma receiving chemotherapy. Integr Cancer Ther. 2013;12:136–44.

    Article  PubMed  Google Scholar 

  17. Mita Y, Dobashi K, Shimizu Y, Nakazawa T, Mori M. Surface expression of toll-like receptor 4 on thp-1 cells is modulated by bu-zhong-yi-qi-tang and shi-quan-da-bu-tang. Methods Find Exp Clin Pharmacol. 2002;24:67–70.

    Article  CAS  PubMed  Google Scholar 

  18. Wu Y, Zhang Y, Wu JA, Lowell T, Gu M, Yuan CS. Effects of erkang, a modified formulation of chinese folk medicine shi-quan-da-bu-tang, on mice. J Ethnopharmacol. 1998;61:153–9.

    Article  CAS  PubMed  Google Scholar 

  19. Tatsuta M, Iishi H, Baba M, Nakaizumi A, Uehara H. Inhibition by shi-quan-da-bu-tang (tj-48) of experimental hepatocarcinogenesis induced by n-nitrosomorpholine in Sprague–Dawley rats. Eur J Cancer. 1994;30A:74–8.

    Article  CAS  PubMed  Google Scholar 

  20. Zee-Cheng RK. Shi-quan-da-bu-tang (ten significant tonic decoction), sqt. A potent chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. Methods Find Exp Clin Pharmacol. 1992;14:725–36.

    CAS  PubMed  Google Scholar 

  21. Sakagami Y, Mizoguchi Y, Miyajima K, Kuboi H, Kobayashi K, Kioka K, et al. Antitumor activity of shi-quan-da-bu-tang and its effects on interferon-gamma and interleukin 2 production. Arerugi = [Allergy]. 1988;37:57–60.

    CAS  Google Scholar 

  22. Nishiuchi T, Okutani Y, Yamagishi Y, Fujita T, Imataki O, Ohnishi H, et al. Synergistic effect between juzen-taiho-to, a japanese traditional herbal medicine, and gemcitabine single-agent chemotherapy for advanced biliary tract cancer. J Altern Complement Med. 2013;19:593–7.

    Article  PubMed  Google Scholar 

  23. Sakamoto S, Kudo H, Kuwa K, Suzuki S, Kato T, Kawasaki T, et al. Anticancer effects of a chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats. Am J Chinese Med. 1991;19:233–41.

    Article  CAS  Google Scholar 

  24. Saiki I. A kampo medicine “juzen-taiho-to”–prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull. 2000;23:677–88.

    Article  CAS  PubMed  Google Scholar 

  25. Lian Z, Niwa K, Gao J, Tagami K, Hashimoto M, Yokoyama Y, et al. Shimotsu-to is the agent in juzen-taiho-to responsible for the prevention of endometrial carcinogenesis in mice. Cancer Lett. 2002;182:19–26.

    Article  CAS  PubMed  Google Scholar 

  26. Abramovitch R, Marikovsky M, Meir G, Neeman M. Stimulation of tumour growth by wound-derived growth factors. Br J Cancer. 1999;79:1392–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was financially supported by National Nature Science Foundation of China (no. 81273733).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, 164 Lanxi Road, Putuo District, Shanghai, 200062, China

    Yong Zhang, Ao Li, Weizhen Peng, Jue Sun, Fangming Xu & Jianhua Xu

Authors
  1. Yong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weizhen Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jue Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fangming Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jianhua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianhua Xu.

Additional information

The Publisher and Editor retract this article in accordance with the recommendations of the Committee on Publication Ethics (COPE). After a thorough investigation we have strong reason to believe that the peer review process was compromised.

An erratum to this article is available at http://dx.doi.org/10.1007/s13277-017-5487-6.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Li, A., Peng, W. et al. RETRACTED ARTICLE: Efficient inhibition of growth of metastatic cancer cells after resection of primary colorectal cancer by soluble Flt-1. Tumor Biol. 36, 7399–7407 (2015). https://doi.org/10.1007/s13277-015-3434-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3434-y

Keywords

Search

Navigation